TBV update

Some more news on Tiens Biotech Group USA Inc. (TBV) :

Beacon Equity Research
Kris Goldcross, CFA gave an "outperform" rating and a price target of $12.30 when the current price of TBV was already $6.61, back on May 6, 2006! With the price now at $2.99, and a price/earnings below 8, TBV is really undervalued at the moment.

China Daily
Report from November 3, 2006, by Xiao Wang. The most exciting part of this announcement is TBV's partnership with other strategic clients: "Multinationals such as L'Oreal, Pfizer Pharmaceuticals and Shiseido have hammered out long-term partnerships with Tiens, serving as high-end original equipment manufacturers (OEM) and original design manufacturers (ODM) for Tiens. "

This will raise the company's global standing and goodwill, and only increases the potential for acquisition and/or insider buying if the stock remains this undervalued.

Case Study: Tiens Biotech
The original case study on The Million Dollar Portfolio, a case for value.

Case Study: Aspreva Pharmaceuticals
Another related undervalued healthcare case study, on ASPV.